441 related articles for article (PubMed ID: 34093547)
1. Natural Killer Cell-Derived Extracellular Vesicles: Novel Players in Cancer Immunotherapy.
Wu F; Xie M; Hun M; She Z; Li C; Luo S; Chen X; Wan W; Wen C; Tian J
Front Immunol; 2021; 12():658698. PubMed ID: 34093547
[TBL] [Abstract][Full Text] [Related]
2. Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors.
Federici C; Shahaj E; Cecchetti S; Camerini S; Casella M; Iessi E; Camisaschi C; Paolino G; Calvieri S; Ferro S; Cova A; Squarcina P; Bertuccini L; Iosi F; Huber V; Lugini L
Front Immunol; 2020; 11():262. PubMed ID: 32231660
[TBL] [Abstract][Full Text] [Related]
3. Tricking the balance: NK cells in anti-cancer immunity.
Pahl J; Cerwenka A
Immunobiology; 2017 Jan; 222(1):11-20. PubMed ID: 26264743
[TBL] [Abstract][Full Text] [Related]
4. Cancer extracellular vesicles as novel regulators of NK cell response.
Soriani A; Vulpis E; Cuollo L; Santoni A; Zingoni A
Cytokine Growth Factor Rev; 2020 Feb; 51():19-26. PubMed ID: 31837917
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cell-Derived Vesicular miRNAs: A New Anticancer Approach?
Fabbri M
Cancer Res; 2020 Jan; 80(1):17-22. PubMed ID: 31672842
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming.
Zhu L; Kalimuthu S; Oh JM; Gangadaran P; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
Biomaterials; 2019 Jan; 190-191():38-50. PubMed ID: 30391801
[TBL] [Abstract][Full Text] [Related]
7. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
8. Back to the Future: Spatiotemporal Determinants of NK Cell Antitumor Function.
Li JH; O'Sullivan TE
Front Immunol; 2021; 12():816658. PubMed ID: 35082797
[TBL] [Abstract][Full Text] [Related]
9. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cells in cancer biology and therapy.
Wu SY; Fu T; Jiang YZ; Shao ZM
Mol Cancer; 2020 Aug; 19(1):120. PubMed ID: 32762681
[TBL] [Abstract][Full Text] [Related]
11. Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy.
Hosseini R; Sarvnaz H; Arabpour M; Ramshe SM; Asef-Kabiri L; Yousefi H; Akbari ME; Eskandari N
Mol Cancer; 2022 Jan; 21(1):15. PubMed ID: 35031075
[TBL] [Abstract][Full Text] [Related]
12. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
13. Professional killers: The role of extracellular vesicles in the reciprocal interactions between natural killer, CD8+ cytotoxic T-cells and tumour cells.
Del Vecchio F; Martinez-Rodriguez V; Schukking M; Cocks A; Broseghini E; Fabbri M
J Extracell Vesicles; 2021 Apr; 10(6):e12075. PubMed ID: 33815694
[TBL] [Abstract][Full Text] [Related]
14. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
15. Proteome Analysis of Human Natural Killer Cell Derived Extracellular Vesicles for Identification of Anticancer Effectors.
Choi JW; Lim S; Kang JH; Hwang SH; Hwang KC; Kim SW; Lee S
Molecules; 2020 Nov; 25(21):. PubMed ID: 33182448
[TBL] [Abstract][Full Text] [Related]
16. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
17. Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity.
Tumino N; Besi F; Martini S; Di Pace AL; Munari E; Quatrini L; Pelosi A; Fiore PF; Fiscon G; Paci P; Scordamaglia F; Covesnon MG; Bogina G; Mingari MC; Moretta L; Vacca P
Front Immunol; 2021; 12():803014. PubMed ID: 35116033
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells and cancer therapy, what we know and where we are going.
Ghaemdoust F; Keshavarz-Fathi M; Rezaei N
Immunotherapy; 2019 Oct; 11(14):1231-1251. PubMed ID: 31422725
[TBL] [Abstract][Full Text] [Related]
19. Immunoregulatory functions and therapeutic potential of natural killer cell-derived extracellular vesicles in chronic diseases.
He S; Su L; Hu H; Liu H; Xiong J; Gong X; Chi H; Wu Q; Yang G
Front Immunol; 2023; 14():1328094. PubMed ID: 38239346
[TBL] [Abstract][Full Text] [Related]
20. Extracellular vesicles in immunomodulation and tumor progression.
Marar C; Starich B; Wirtz D
Nat Immunol; 2021 May; 22(5):560-570. PubMed ID: 33753940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
